Maintains integrated ´Grade A´ despite stricter evaluation criteria, demonstrating continuous refinement of its ESG management framework

Proactively aligns with global standards by adopting the TNFD framework and integrating overseas subsidiary data

Enhances corporate trust by strengthening human rights, safety & health, supply chain management, and responsible governance

SK bioscience announced today that it has achieved an ‘Integrated Grade A’ in the ´2026 ESG Evaluation´ conducted by the Korea Institute of Corporate Governance and Sustainability (KCGS).

This marks the fifth consecutive year that SK bioscience has maintained an ´A´ rating since first receiving it in 2022. The result recognizes the company´s achievements in continuously advancing its ESG management system and operational capabilities amidst a rapidly evolving sustainability landscape.

The KCGS ESG Evaluation is a comprehensive assessment system evaluating major listed Korean companies across Environmental (E), Social (S), and Governance (G) categories, covering corporate policies, management systems, operational performance, and disclosure transparency. SK bioscience actively navigated the shifting evaluation standards by enhancing its management infrastructure across all sectors and expanding public disclosures.

SK bioscience drives ESG as a core business strategy to ensure sustainable growth and maximize corporate value. The company has established a robust foundation for execution, with the ESG Committee under the Board of Directors (BOD) reviewing major policies and strategies, while a dedicated ESG team and working group drive task execution and performance management across departments. In addition, the company continues to reinforce its risk management systems to enhance the practical effectiveness of responsible management.

In the Environmental (E) category, SK bioscience has advanced its climate change response and natural impact management systems. Notably, by introducing the Taskforce on Nature-related Financial Disclosures (TNFD) framework, the company evaluated the impacts of its operations on nature and biodiversity, derived risk and opportunity factors, and formulated strategic responses. It also enhanced transparency in green initiatives by disclosing renewable energy usage from solar installations at its Songdo headquarters. Alongside key performance indicator (KPI) management for greenhouse gas emissions, energy/water consumption, and waste, SK bioscience continues its energy-saving efforts and eco-friendly process improvements centered around its ´L HOUSE´ manufacturing facility in Andong. Driven by these efforts, the company´s Environmental rating upgraded to an ´A´ this year from a ´B+´ last year.

In the Social (S) category, the company has expanded its social responsibility practices around human rights management, health & safety, and sustainable supply chain management. SK bioscience systematically identifies and manages key human rights risks while strengthening policy compliance and training for employees and partners. It also creates social value through community engagement and CSR initiatives. Furthermore, as a global vaccine provider, the company continues to broaden its role in expanding medicine accessibility and improving public health.

In the Governance (G) category, SK bioscience focuses on board-centric responsible management and transparent decision-making practices. The company has enhanced the independence and expertise of its Board and sub-committees, while refining Audit Committee operations and internal control systems. Information disclosure and stakeholder communications have also been continually expanded to maximize corporate governance transparency and trustworthiness.

"ESG is a strategic mandate for achieving sustainable growth and fulfilling our corporate social responsibilities," said Jaeyoung Choi, Head of Corporate Support Division at SK bioscience. "We will continue to proactively address evolving global ESG standards and stakeholder expectations, strengthening management capabilities across E, S, and G to simultaneously elevate our business value and societal impact."

Since 2022, SK bioscience has published an annual ESG Report to transparently disclose its sustainability strategies and achievements. Notably, the company expanded the scope and credibility of its ESG reporting by integrating data from its German subsidiary, IDT Biologika, and adopting evaluation models based on global sustainability disclosure standards. Going forward, SK bioscience plans to consolidate its sustainable growth and public trust grounded in a world-class ESG management framework.